I am a cell and molecular biologist and co-founder of ProtLLM Inc., an AI/ML-driven antibody discovery startup tackling oncology and neurology's hardest targets intrinsically disordered proteins and neoantigens that have long resisted conventional approaches.

My work bridges wet lab science and computational biology, translating protein language models into therapeutic tools. At ProtLLM, I am building a platform combining proprietary antibody design technology with a CRO-style service model, giving biotech and academic partners access to next-generation biologics discovery.

My mission: close the gap between AI-driven protein science and real-world therapeutic impact.